New Products & Services

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.